

RESEARCH

[Sector Report] Automobiles

Mixed signals – prefer PVs, two-wheelers

BOB Economics Research | Weekly Wrap

Union Budget to take centre-stage

Kotak Mahindra Bank | Target: Rs 1,875 | +16% | BUY

Growth slips while credit cost spikes

SUMMARY

Automobiles

The auto industry slump over the past five quarters has seen the Nifty Auto Index plunging ~40% over the 12 months to Sep'19. Subsequent improvement in retail sales and the corporate tax cut have aided a 25% pullback in the auto index. In our view, a low base, good monsoons and gradual macro revival should aid a cyclical recovery in auto volumes from FY21. But looming challenges from new emission norms and continued capacity overhang (in CVs) warrant a selective stock approach – MSIL & EIM are top picks; we are cautious on HMCL, TVSL & AL.

[Click here for the full report.](#)

India Economics: Weekly Wrap

US equity markets surged to new highs on the back of signing of US-China trade deal and positive macro data in US (retail sales, housing starts) and China (GDP, industrial production, investments). However, 10Y yields in UK slipped by 14bps after data surprised negatively (industrial production, inflation). On the domestic front, India's CPI and WPI inched up on the back of food inflation. So did bond yields. In the coming days, focus will be on policy measures to revive growth that could be announced in the Union Budget.

[Click here for the full report.](#)

TOP PICKS

LARGE-CAP IDEAS

Company	Rating	Target
Cipla	Buy	570
ONGC	Buy	210
Petronet LNG	Buy	400
Reliance Industries	Buy	1,860
TCS	Add	2,390

MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	2,290
Future Supply	Buy	680
Greenply Industries	Buy	210
Laurus Labs	Buy	480
PNC Infratech	Buy	245

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.82	1bps	(6bps)	(96bps)
India 10Y yield (%)	6.63	2bps	(13bps)	(68bps)
USD/INR	64.85	0.4	(1.9)	3.4
Brent Crude (US\$/bbl)	71.08	(0.2)	(0.2)	0.1
Dow	29,348	0.2	3.8	18.8
Shanghai	3,075	0	1.8	18.5
Sensex	41,945	0	1.4	15.3
India FII (US\$ mn)	16 Jan	MTD	CYTD	FYTD
FII-D	30.1	(1,132.7)	(1,132.7)	1,811.4
FII-E	1,372.5	1,714.9	1,714.9	9,104.1

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



Kotak Mahindra Bank

Kotak Mahindra Bank's (KMB) Q3FY20 PAT at Rs 16bn was below estimates due to weak NII growth and high provisions. Key disappointments were loan growth slipping to a multi-quarter low of 10% YoY and 9MFY20 credit cost spiking to 67bps. Management has toned down its growth guidance from the mid-teens to 10-15% YoY but believes credit cost for FY20 can be held ~60bps. The SMA-2 book declined to Rs 2.7bn (0.1% of loans) given some lumpy corporate slippages. We cut FY20-FY22 EPS by 6-7% and revise our TP to Rs 1,875 (vs. Rs 1,950).

[Click here](#) for the full report.

AUTOMOBILES

20 January 2020

Mixed signals – prefer PVs, two-wheelers

The auto industry slump over the past five quarters has seen the Nifty Auto Index plunging ~40% over the 12 months to Sep'19. Subsequent improvement in retail sales and the corporate tax cut have aided a 25% pullback in the auto index. In our view, a low base, good monsoons and gradual macro revival should aid a cyclical recovery in auto volumes from FY21. But looming challenges from new emission norms and continued capacity overhang (in CVs) warrant a selective stock approach – MSIL & EIM are top picks; we are cautious on HMCL, TVSL & AL.

Navin Matta | Nishant Chowhan, CFA
 research@bobcaps.in

Expect a cyclical recovery...: FY20 is likely to close with record low volume sales growth across major automotive segments. That said, the recent pickup in retail growth for passenger vehicles (PV) and two-wheelers (2W) during the Oct'19 festive season points to demand recovering in end-markets. A soft base, above average monsoons this year and gradual economic recovery should spur a cyclical rebound in volume growth from the next fiscal. However, with yet another regulatory-led cost push from new BS-VI emission norms in Apr'20, we do not envisage a V-shaped recovery.

...but recommend a selective approach: We prefer the PV segment given low incremental cost pressure from BS-VI changeover (in petrol models), moderate competitive stress and possible unlocking of pent-up demand. In 2Ws, we favour companies with a diversified mix or those with a lesser exposure to mass-market segments. The commercial vehicle (CV) segment warrants a cautious view due to a persistent supply overhang from the sharp rise in system capacity, stiff regulatory-led cost burden, and risk of freight movement shifting to rail upon dedicated freight corridor (DFC) commissioning in FY21.

Valuations above median, yet sustainable: In the past five years, auto sector valuations have rerated by ~20% compared to the preceding cycle. At 21x, the current one-year forward P/E multiple is above the median for the sector. In our view, valuations look sustainable as expected earnings recovery will trigger improvement in return ratios (ex-cash) and free cash flows.

Top picks: Building in prospects of a cyclical revival as well as structural hindrances, we identify Maruti Suzuki (MSIL) and Eicher Motors (EIM) as top picks. We have ADD ratings on Bajaj Auto (BJAUT), Tata Motors (TTMT) and Mahindra & Mahindra (MM). We are cautious on Hero MotoCorp (HMCL, REDUCE) and TVS Motor (TVSL, REDUCE), but negative on Ashok Leyland (AL, SELL).

RECOMMENDATION SNAPSHOT

Ticker	Price	Target	Rating
AL IN	84	68	SELL
BJAUT IN	3,118	3,470	ADD
EIM IN	21,292	25,000	BUY
HMCL IN	2,454	2,575	REDUCE
MM IN	569	625	ADD
MSIL IN	7,520	8,900	BUY
TTMT IN	197	220	ADD
TVSL IN	485	465	REDUCE

Price & Target in Rupees



WEEKLY WRAP

20 January 2020

Union Budget to take centre-stage

US equity markets surged to new highs on the back of signing of US-China trade deal and positive macro data in US (retail sales, housing starts) and China (GDP, industrial production, investments). However, 10Y yields in UK slipped by 14bps after data surprised negatively (industrial production, inflation). On the domestic front, India's CPI and WPI inched up on the back of food inflation. So did bond yields. In the coming days, focus will be on policy measures to revive growth that could be announced in the Union Budget.

Sameer Narang | Sonal Badhan

chief.economist@bankofbaroda.com

Markets

- **Bonds:** Global yields closed mixed even after US and China signed Phase 1 trade deal. US 10Y yield closed flat at 1.82%. UK 10Y yield fell by 14bps as economic data disappointed. Oil prices fell by (-) 0.2% due to easing tensions in Middle East. India's 10Y yield rose by 4bps (6.63%) as headline CPI print in Dec'19 rose to a 5-year high of 7.4%. System liquidity surplus was at Rs 3.1tn as on 17 Jan 2020 vs Rs 3.2tn in the previous week.
- **Currency:** Except CNY, other global currencies closed lower this week. DXY rose by 0.3% in the week as US retail sales, jobless claims and housing starts surprised positively. CNY rose by 0.9% to its highest since Jul'19 on the back of signing of US-China trade deal and improved economic data in Dec'19 (exports, retail sales, industrial production and fixed asset investments). INR depreciated by (-) 0.2% in the week even as oil prices eased. FII inflows were US\$ 1.2bn.
- **Equity:** Barring Shanghai Comp (-0.5%), global indices ended higher this week. While investors await more clarity on the phase 1 deal signed between US and China, earnings results and positive macro prints (China GDP, Euro Area inflation, US retail sales) kept the sentiments high in US and Europe. Following global cues, Sensex too ended the week 0.8% higher.
- **Upcoming key events:** In the current week, markets will await policy decisions of major central banks (BoJ, ECB). Apart from this, flash manufacturing data of major economies (US, Germany, France and Japan) will give an idea about manufacturing activity in Jan'20. On the domestic front, markets will await cues on Union Budget.



BUY

TP: Rs 1,875 | ▲ 16%

**KOTAK MAHINDRA
BANK**

| Banking

| 20 January 2020

Growth slips while credit cost spikes

Kotak Mahindra Bank's (KMB) Q3FY20 PAT at Rs 16bn was below estimates due to weak NII growth and high provisions. Key disappointments were loan growth slipping to a multi-quarter low of 10% YoY and 9MFY20 credit cost spiking to 67bps. Management has toned down its growth guidance from the mid-teens to 10-15% YoY but believes credit cost for FY20 can be held ~60bps. The SMA-2 book declined to Rs 2.7bn (0.1% of loans) given some lumpy corporate slippages. We cut FY20-FY22 EPS by 6-7% and revise our TP to Rs 1,875 (vs. Rs 1,950).

Vikesh Mehta

research@bobcaps.in


Slight miss on asset quality: KMB's GNPA ratio increased 14bps QoQ to 2.46%, driven by a couple of lumpy corporate accounts and slippages in SME, CV/CE and small business loans. The SMA-2 book declined to Rs 2.7bn (0.1% of loans) vs. Rs 4.3bn (0.2%) in Q2 given the corporate slippages. Stress in the unsecured personal loan/credit card portfolio has increased but remains in line with the industry, while NPAs in the agriculture segment were largely stable during the quarter. 9MFY20 credit cost stood at 67bps but guidance for FY20 was maintained near 60bps levels. Telecom exposure to stressed players is low.

Ticker/Price	KMB IN/Rs 1,618
Market cap	US\$ 43.5bn
Shares o/s	1,910mn
3M ADV	US\$ 57.0mn
52wk high/low	Rs 1,735/Rs 1,210
Promoter/FPI/DII	30%/40%/30%

Source: NSE

Loan growth at multi-quarter low: Loan growth dropped to ~10% YoY in Q3 largely due to sluggish growth in the corporate (3%) and CV/CE (6%) segments. Low working capital utilisation slowed growth in the corporate segment. The retail segment grew 18% YoY as the agri, home loan and small business segments grew in the range of 15-20%. FY20 loan growth guidance stands lowered from the mid-teens to 10-15% YoY. Management highlighted that its '811' digital banking product is driving strong cross-sales across products – growth in balances from these customers is steady with a rise in savings deposits.

STOCK PERFORMANCE



Source: NSE

Maintain BUY: We cut FY20-FY22 EPS estimates by 6-7% to build in slower growth and higher credit costs, yielding a revised Mar'21 TP of Rs 1,875.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Net interest income	95,317	112,590	133,258	160,501	196,487
NII growth (%)	1729.6	1812.1	1835.7	2044.4	2242.1
Adj. net profit (Rs mn)	40,619	41,632	61,842	77,531	97,975
EPS (Rs)	21.8	25.5	32.4	40.6	51.3
P/E (x)	74.2	63.4	49.9	39.8	31.5
P/BV (x)	8.2	7.3	6.4	5.5	4.8
ROA (%)	1.7	1.7	1.9	2.1	2.2
ROE (%)	12.5	12.2	13.6	14.9	16.3

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.